key: cord-0726473-czjtkm6p
authors: Kumar, Dr. Rohit; Bhattacharya, Dr. Bisakh; Meena, Dr. Vedprakash; Soneja, Dr. Manish; Wig, Dr. Naveet
title: COVID-19 and TB co-infection - 'Finishing touch'' in perfect recipe to 'severity’ or ‘death'
date: 2020-06-29
journal: J Infect
DOI: 10.1016/j.jinf.2020.06.062
sha: d70d6601a80ebe47b098beb300faf692958d15ad
doc_id: 726473
cord_uid: czjtkm6p

nan

of attending a large congregation during this pandemic. On admission, his vitals were -GCS-15, BP-96/50mmHg, PR-92.min, low SpO2-84% (room air), respiratory rate-28/min. Chest X ray revealed diffuse infiltrates bilaterally; laboratory abnormalities included anaemia, normal TLC (neutrophilic), and mild transaminitis. Considering a COVID suspect, fulfilling criteria for SARI (severe acute respiratory illness), his nasopharyngeal and oropharyngeal swab was Coinfection with TB and SARS CoV-2 is of particular concern due to several reasons. Firstly, diagnosis of TB is likely to be missed due to non-specific clinical features in both (TB & COVID-19) and lack of radiological findings specific to TB. Secondly, this disease itself or use of immunomodulators in moderate-severe COVID-19 may lead to reactivation of latent TB in high endemic areas like India (3, 4) . Thirdly, pre-existing TB disease and underlying lung condition will affect the clinical categorisation (for severity) of COVID-19. Fourth, coexisting active TB disease may predispose to severe illness (5, 6) . Lastly, there is possibility of drug-drug interactions (e.g. Rifampicin and Lopinavir/ritonavir) as well as additive hepatotoxicity (remdisivir) due to simultaneous use of anti-tubercular drugs and available COVID-19 therapeutic options(7).

To conclude, co-infections with TB must always be suspected in addition to COVID-19 in current scenario in patients with RTI with non-specific clinical features and unexplained or prolonged clinical course and utmost consideration should be given to all above concerns implicated.

Fundingno funding required or received

Co-infections in people with COVID-19: a systematic review and meta-analysis

Co-infections: potentially lethal and unexplored in COVID-19. Lancet Microbe

Corona virus activates a stem cell mediated defense mechanism that accelerates activation of dormant tuberculosis: implications for the COVID-19 pandemic. bioRxiv

Increased risk of mycobacterial infections associated with anti-rheumatic medications

Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity

Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases

Author contribution -RKconceived the idea. RK, BB, VM were involved in the preparation of manuscript. VM, MS, NW were involved in the editing and proof reading.All authors are actively involved in management of COVID cases in their institute.